
Health Catalyst fell 32.6% from $2.24 to $1.51, behind the S&P 500's +13.3%. Its worst day was Mar 13 (−26.3%), and its low came Apr 10 at $1.00.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Health Catalyst closed at its highest level of the year, 33.5% above where the year started.
+2.4% · S&P 500 +0.5%
EPS of $0.08 missed the $0.10 estimate on $74.7M revenue (est. $73.8M); Q1 revenue guidance of $68.0M–$70.0M against the $74.1M consensus.
Story events cover the past 12 months · Times ET
−26.3%, the year's worst day · S&P 500 −0.6%
Health Catalyst closed at its lowest level of the year, 55.5% below where the year started.
−1.4% · S&P 500 −0.1%
Health Catalyst shares rose 16.0%, while the S&P 500 rose 0.3%.
+16.0% · S&P 500 +0.3%
EPS of $0.02 beat the $-0.01 estimate on $70.8M revenue (est. $69.2M); Q2 revenue guidance of $68.0M–$70.0M against the $70.7M consensus.
+7.2% · S&P 500 −0.2%
Health Catalyst shares rose 45.9%, while the S&P 500 rose 0.4%.
+45.9%, the year's best day, on 28M shares, the year's heaviest volume · S&P 500 +0.4%
EPS of $0.04 beat the $0.01 estimate on $70.5M revenue (est. $69.0M); FY revenue guidance of $246.0M–$249.0M against the $263.1M consensus.
−25.1% · S&P 500 +0.6%
EPS of $-0.03 beat the $-0.05 estimate on $56.3M revenue (est. $55.3M); FY revenue guidance of $246.0M–$249.0M against the $247.7M consensus.
−2.7% · S&P 500 +0.3%
Where it ended: a close of $1.51 on Nov 13, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.06, revenue est. $50.7M).
Nothing in the past 12 months.
All HCAT dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for HCAT and SPY from Benzinga historical bars. Not investment advice.